Healio Tyrosine Kinase Inhibitors: Transforming nAMD Treatment
Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age-related macular degeneration (nAMD), addressing the significant burden associated with frequent anti-vascular endothelial growth factor (VEGF) injections. The inhibition of tyrosine kinases blocks the activation of VEGF receptor and platelet-derived growth factor receptor, thereby reducing angiogenesis and vascular leakage. Unlike current anti-VEGF agents that act extracellularly, TKIs target intracellular pathways, providing a complementary mechanism of action. Sustained-release TKI implants have demonstrated extended durability in clinical trials, potentially reducing treatment frequency and improving adherence. Ongoing studies have shown efficacy comparable to traditional therapies, with fewer injections and no significant adverse events. In this CE activity, expert faculty identify the challenges associated with anti-VEGF use in patients with nAMD, describe the rationale for targeting tyrosine kinases, and review the most recent clinical data on TKIs for treating nAMD.
Cost: Free
View Offer chevron_rightDetails
Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age-related macular degeneration (nAMD), addressing the significant burden associated with frequent anti-vascular endothelial growth factor (VEGF) injections. The inhibition of tyrosine kinases blocks the activation of VEGF receptor and platelet-derived growth factor receptor, thereby reducing angiogenesis and vascular leakage. Unlike current anti-VEGF agents that act extracellularly, TKIs target intracellular pathways, providing a complementary mechanism of action. Sustained-release TKI implants have demonstrated extended durability in clinical trials, potentially reducing treatment frequency and improving adherence. Ongoing studies have shown efficacy comparable to traditional therapies, with fewer injections and no significant adverse events. In this CE activity, expert faculty identify the challenges associated with anti-VEGF use in patients with nAMD, describe the rationale for targeting tyrosine kinases, and review the most recent clinical data on TKIs for treating nAMD.
Topics Covered
Tyrosine Kinase Inhibitors, nAMD Treatment
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Identify the challenges associated with anti-VEGF use for patients with nAMD and explain how these challenges lead to undertreatment.
- Describe the rationale for targeting tyrosine kinases in the management of patients with nAMD.
- Summarize the most recent clinical data on tyrosine kinase inhibitors for treating patients with nAMD.
Target Audience
The intended audience for this activity is retina specialists involved in the management of patients with nAMD.
Additional credit info
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.